Login to Your Account

Clinic Roundup

Tuesday, October 1, 2013
• Lithera Inc., of San Diego, reported positive results from its 513-patient Phase IIb RESET study of LIPO-202 (salmeterol xinafoate for Injection) designed to measure safety and efficacy of three different doses (0.4, 1 and 4 mcg [total dose]) in healthy, non-obese subjects with abdominal bulging due to excess subcutaneous fat.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription